TRACON Pharmaceuticals announces positive data from ongoing phase 1b/2 trial of TRC105
TRACON Pharmaceuticals announced positive initial clinical data from its ongoing Phase 1b/2 study of TRC105 and Nexavar® (sorafenib) in patients with advanced hepatocellular carcinoma. Partial responses by RECIST 1.1 occurred in 2 of 8 (25%) evaluable patients. January 19, 2018